Cargando…
The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy
Objectives: To evaluate the efficacy and health economics of four treatments for type 1 cesarean scar pregnancy (CSP). Methods: From January 2009 to December 2018, 326 patients diagnosed with type 1 CSP were examined, among whom 31 received ultrasound-guided local injection of methotrexate (local in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831712/ https://www.ncbi.nlm.nih.gov/pubmed/35153794 http://dx.doi.org/10.3389/fphar.2022.822319 |
_version_ | 1784648562431229952 |
---|---|
author | Hong, Tingting Chai, Zeying Liu, Manman Zheng, Lingzhi Qi, Feng |
author_facet | Hong, Tingting Chai, Zeying Liu, Manman Zheng, Lingzhi Qi, Feng |
author_sort | Hong, Tingting |
collection | PubMed |
description | Objectives: To evaluate the efficacy and health economics of four treatments for type 1 cesarean scar pregnancy (CSP). Methods: From January 2009 to December 2018, 326 patients diagnosed with type 1 CSP were examined, among whom 31 received ultrasound-guided local injection of methotrexate (local injection group), 160 patients received uterine artery embolization combined with suction aspiration (UAE group), 25 patients received ultrasound-guided suction aspiration (aspiration group) and 90 received ultrasound-guided local injection of lauromacrogol combined with suction aspiration (lauromacrogol group). Clinical data and outcomes were analyzed. The decision tree model was used to compare the economics of four treatments. Results: The success rate of the local injection group was 71.0% (22/31), which was significantly different from 98.8% (158/160) of the UAE group and 100.0% (90/90) of the lauromacrogol group. The success rate of the aspiration group was 92.0% (23/25), which was significantly lower than that of the lauromacrogol group. The cost-effectiveness ratio was 1,876.53 yuan for the aspiration group, 2,164.63 yuan for the lauromacrogol group, 4,383.56 yuan for the local injection group, and 7,850.81 yuan for the UAE group. The Incremental cost effectiveness ratio (ICER) of the lauromacrogol group to the aspiration group was 5,477.75 yuan, indicating that if the willing to pay of patients was higher than 5,477.75 yuan, the lauromacrogol group had a cost-effectiveness advantage in treating type 1 CSP, compared to aspiration group. On the contrary, aspiration group has a higher cost-effectiveness advantage. The ICER of the lauromacrogol group to the local injection group or the UAE group were both less than 0, indicating that local injection group and UAE group was not cost-effective in the treatment of type 1 CSP. Conclusion: For type 1 CSP, the ultrasound-guided local injection of lauromacrogol combined with suction aspiration and ultrasound-guided suction aspiration, are effective and economical, and the choice between the two can be based on the patient’s willing to pay. |
format | Online Article Text |
id | pubmed-8831712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88317122022-02-12 The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy Hong, Tingting Chai, Zeying Liu, Manman Zheng, Lingzhi Qi, Feng Front Pharmacol Pharmacology Objectives: To evaluate the efficacy and health economics of four treatments for type 1 cesarean scar pregnancy (CSP). Methods: From January 2009 to December 2018, 326 patients diagnosed with type 1 CSP were examined, among whom 31 received ultrasound-guided local injection of methotrexate (local injection group), 160 patients received uterine artery embolization combined with suction aspiration (UAE group), 25 patients received ultrasound-guided suction aspiration (aspiration group) and 90 received ultrasound-guided local injection of lauromacrogol combined with suction aspiration (lauromacrogol group). Clinical data and outcomes were analyzed. The decision tree model was used to compare the economics of four treatments. Results: The success rate of the local injection group was 71.0% (22/31), which was significantly different from 98.8% (158/160) of the UAE group and 100.0% (90/90) of the lauromacrogol group. The success rate of the aspiration group was 92.0% (23/25), which was significantly lower than that of the lauromacrogol group. The cost-effectiveness ratio was 1,876.53 yuan for the aspiration group, 2,164.63 yuan for the lauromacrogol group, 4,383.56 yuan for the local injection group, and 7,850.81 yuan for the UAE group. The Incremental cost effectiveness ratio (ICER) of the lauromacrogol group to the aspiration group was 5,477.75 yuan, indicating that if the willing to pay of patients was higher than 5,477.75 yuan, the lauromacrogol group had a cost-effectiveness advantage in treating type 1 CSP, compared to aspiration group. On the contrary, aspiration group has a higher cost-effectiveness advantage. The ICER of the lauromacrogol group to the local injection group or the UAE group were both less than 0, indicating that local injection group and UAE group was not cost-effective in the treatment of type 1 CSP. Conclusion: For type 1 CSP, the ultrasound-guided local injection of lauromacrogol combined with suction aspiration and ultrasound-guided suction aspiration, are effective and economical, and the choice between the two can be based on the patient’s willing to pay. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8831712/ /pubmed/35153794 http://dx.doi.org/10.3389/fphar.2022.822319 Text en Copyright © 2022 Hong, Chai, Liu, Zheng and Qi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Hong, Tingting Chai, Zeying Liu, Manman Zheng, Lingzhi Qi, Feng The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy |
title | The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy |
title_full | The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy |
title_fullStr | The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy |
title_full_unstemmed | The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy |
title_short | The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy |
title_sort | efficacy and health economics of different treatments for type 1 cesarean scar pregnancy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831712/ https://www.ncbi.nlm.nih.gov/pubmed/35153794 http://dx.doi.org/10.3389/fphar.2022.822319 |
work_keys_str_mv | AT hongtingting theefficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT chaizeying theefficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT liumanman theefficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT zhenglingzhi theefficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT qifeng theefficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT hongtingting efficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT chaizeying efficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT liumanman efficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT zhenglingzhi efficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy AT qifeng efficacyandhealtheconomicsofdifferenttreatmentsfortype1cesareanscarpregnancy |